Cationic gemini lipopeptides
are a relatively new class of amphiphilic
compounds to be used for gene delivery. Through the possibility of
incorporating short peptides with cell-penetrating functionalities,
these lipopeptides may be advantageous over traditional cationic lipids.
Herein, we report the design, synthesis, and application of a novel
cationic gemini lipopeptide for gene delivery. An ultrashort peptide,
containing four amino acids, arginine–cysteine–cysteine–arginine,
serves as a cationic head group, and two α-tocopherol moieties
act as hydrophobic anchoring groups. The new lipopeptide (ATTA) is
incorporated into the conventional liposomes, containing 1,2-dioleoyl-3-trimethylammonium-propane
(DOTAP) and 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE),
at different molar ratios. The formulated liposomes are characterized
and screened for better transfection efficiency. Transfection activity
in multiple human cell lines from cancerous and noncancerous origins
indicates that the inclusion of an optimal ratio of ATTA in the liposomes
substantially enhances the transfection efficiency, superior to that
of a traditional liposome, DOTAP–DOPE. Cytotoxicity of ATTA-containing
formulations against multiple cell lines indicates potentially distinct
activity between cancer and noncancer cell lines. Furthermore, lipoplexes
of the ATTA-containing formulations with anticancer therapeutic gene,
plasmid encoding tumor necrosis factor-related apoptosis-inducing
ligand (pTRAIL), induce obviously more cytotoxicity than conventional
formulations. The results indicate that arginine-rich cationic lipopeptide
appears to be a promising ingredient in gene delivery vector formulations
to enhance transfection efficiency and cell-selective cytotoxicity.